Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) announced preliminary unaudited net revenues and cash balances for Q4 and FY 2020, to be discussed at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. Novocure plans to discuss these results with investors at the 39th Annual J.P. Morgan Virtual Healthcare Conference. Novocure also plans to highlight key clinical and product development programs.
Fourth quarter and full year 2020 highlights include: |
||||||||||||||||||||||||||||||||||||||
|
Three months ended
|
|
Twelve months ended
|
|
||||||||||||||||||||||||||||||||||
|
|
2020 |
|
|
2019 |
|
% Change |
|
|
2020 |
|
|
2019 |
|
% Change |
|
||||||||||||||||||||||
|
|
(unaudited) |
|
|
(audited) |
|||||||||||||||||||||||||||||||||